PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 330.62% | 1,391.60% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 330.62% | 1,391.60% | -- | -- | -- |
| Cost of Revenue | 308.63% | 1,257.98% | -- | -- | -- |
| Gross Profit | 366.94% | 1,652.70% | -- | -- | -- |
| SG&A Expenses | 52.14% | 174.49% | 402.09% | 349.47% | 1,004.35% |
| Depreciation & Amortization | 190.29% | 731.10% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 136.47% | 421.46% | 1,470.07% | 1,520.83% | 1,584.89% |
| Operating Income | 55.71% | 45.94% | 194.81% | 243.68% | -746.58% |
| Income Before Tax | 56.60% | 62.10% | 267.98% | 377.03% | -852.39% |
| Income Tax Expenses | -2,383.33% | 57,200.00% | -- | -- | -- |
| Earnings from Continuing Operations | 58.55% | 35.79% | 217.98% | 425.17% | -853.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1,123.08% | 200.00% | -- | -- | -- |
| Net Income | 56.62% | 36.24% | 212.25% | 441.35% | -851.46% |
| EBIT | 55.71% | 45.94% | 194.81% | 243.68% | -746.58% |
| EBITDA | 71.24% | 72.60% | -- | -- | -- |
| EPS Basic | 58.73% | 69.23% | 118.92% | 158.97% | -70.27% |
| Normalized Basic EPS | 53.85% | 81.63% | 128.26% | 153.06% | -69.57% |
| EPS Diluted | 58.73% | 69.23% | 118.92% | 158.97% | -70.27% |
| Normalized Diluted EPS | 53.85% | 81.63% | 128.26% | 153.06% | -69.57% |
| Average Basic Shares Outstanding | 3.66% | 110.80% | 478.43% | 479.64% | 458.02% |
| Average Diluted Shares Outstanding | 3.66% | 110.80% | 478.43% | 479.64% | 458.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |